These overall aggregated results showed SGLT-2 inhibitors reduced risk of cardiovascular death or hospitalization for HF, and risk of kidney disease progression (defined as a ≥40% decline in eGFR) by about 25%. The gene discussed is SLC5A2; the disease is kidney disorder.